nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—Ulcer—Methotrexate—systemic scleroderma	0.00362	0.00362	CcSEcCtD
Pentazocine—Chills—Leflunomide—systemic scleroderma	0.00361	0.00361	CcSEcCtD
Pentazocine—Agranulocytosis—Lisinopril—systemic scleroderma	0.0036	0.0036	CcSEcCtD
Pentazocine—Tinnitus—Mycophenolic acid—systemic scleroderma	0.00358	0.00358	CcSEcCtD
Pentazocine—Paraesthesia—Mometasone—systemic scleroderma	0.00355	0.00355	CcSEcCtD
Pentazocine—Dry mouth—Captopril—systemic scleroderma	0.00354	0.00354	CcSEcCtD
Pentazocine—Dyspnoea—Mometasone—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Pentazocine—Euphoric mood—Prednisone—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Pentazocine—Confusional state—Captopril—systemic scleroderma	0.0035	0.0035	CcSEcCtD
Pentazocine—Anaphylactic shock—Captopril—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Pentazocine—Chills—Mycophenolic acid—systemic scleroderma	0.00345	0.00345	CcSEcCtD
Pentazocine—Hallucination—Lisinopril—systemic scleroderma	0.00344	0.00344	CcSEcCtD
Pentazocine—Decreased appetite—Mometasone—systemic scleroderma	0.00344	0.00344	CcSEcCtD
Pentazocine—Dysgeusia—Leflunomide—systemic scleroderma	0.00343	0.00343	CcSEcCtD
Pentazocine—Shock—Captopril—systemic scleroderma	0.00342	0.00342	CcSEcCtD
Pentazocine—Tachycardia—Captopril—systemic scleroderma	0.00339	0.00339	CcSEcCtD
Pentazocine—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00338	0.00338	CcSEcCtD
Pentazocine—Muscle spasms—Leflunomide—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Pentazocine—Anorexia—Captopril—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Pentazocine—Vision blurred—Leflunomide—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Pentazocine—Asthenia—Pentoxifylline—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Pentazocine—Erythema multiforme—Lisinopril—systemic scleroderma	0.00327	0.00327	CcSEcCtD
Pentazocine—Hypotension—Captopril—systemic scleroderma	0.00324	0.00324	CcSEcCtD
Pentazocine—Pruritus—Pentoxifylline—systemic scleroderma	0.00324	0.00324	CcSEcCtD
Pentazocine—Sweating—Mycophenolate mofetil—systemic scleroderma	0.00324	0.00324	CcSEcCtD
Pentazocine—Tinnitus—Lisinopril—systemic scleroderma	0.00323	0.00323	CcSEcCtD
Pentazocine—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00322	0.00322	CcSEcCtD
Pentazocine—Flushing—Lisinopril—systemic scleroderma	0.00321	0.00321	CcSEcCtD
Pentazocine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Pentazocine—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Pentazocine—Vertigo—Leflunomide—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Pentazocine—Insomnia—Captopril—systemic scleroderma	0.00314	0.00314	CcSEcCtD
Pentazocine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Pentazocine—Tremor—Mycophenolic acid—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Pentazocine—Paraesthesia—Captopril—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Pentazocine—Chills—Lisinopril—systemic scleroderma	0.00311	0.00311	CcSEcCtD
Pentazocine—Dyspnoea—Captopril—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Pentazocine—Somnolence—Captopril—systemic scleroderma	0.00309	0.00309	CcSEcCtD
Pentazocine—Agitation—Mycophenolic acid—systemic scleroderma	0.00307	0.00307	CcSEcCtD
Pentazocine—Dizziness—Pentoxifylline—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Pentazocine—Hypertension—Leflunomide—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Pentazocine—Decreased appetite—Captopril—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Pentazocine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Pentazocine—Vertigo—Mycophenolic acid—systemic scleroderma	0.00301	0.00301	CcSEcCtD
Pentazocine—Syncope—Mycophenolic acid—systemic scleroderma	0.003	0.003	CcSEcCtD
Pentazocine—Constipation—Captopril—systemic scleroderma	0.00297	0.00297	CcSEcCtD
Pentazocine—Dysgeusia—Lisinopril—systemic scleroderma	0.00295	0.00295	CcSEcCtD
Pentazocine—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Pentazocine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00292	0.00292	CcSEcCtD
Pentazocine—Dry mouth—Leflunomide—systemic scleroderma	0.00292	0.00292	CcSEcCtD
Pentazocine—Vomiting—Pentoxifylline—systemic scleroderma	0.00291	0.00291	CcSEcCtD
Pentazocine—Muscle spasms—Lisinopril—systemic scleroderma	0.0029	0.0029	CcSEcCtD
Pentazocine—Hypertension—Mycophenolic acid—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Pentazocine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Pentazocine—Headache—Pentoxifylline—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Pentazocine—Face oedema—Prednisone—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Pentazocine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Pentazocine—Feeling abnormal—Captopril—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Pentazocine—Vision blurred—Lisinopril—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Pentazocine—Asthenia—Mometasone—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Pentazocine—Irritability—Prednisone—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Pentazocine—Hypotension—Azathioprine—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Pentazocine—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Pentazocine—Tremor—Lisinopril—systemic scleroderma	0.00282	0.00282	CcSEcCtD
Pentazocine—Pruritus—Mometasone—systemic scleroderma	0.0028	0.0028	CcSEcCtD
Pentazocine—Tachycardia—Leflunomide—systemic scleroderma	0.00279	0.00279	CcSEcCtD
Pentazocine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00278	0.00278	CcSEcCtD
Pentazocine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00277	0.00277	CcSEcCtD
Pentazocine—Confusional state—Mycophenolic acid—systemic scleroderma	0.00275	0.00275	CcSEcCtD
Pentazocine—Anorexia—Leflunomide—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Pentazocine—Nausea—Pentoxifylline—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Pentazocine—Chills—Mycophenolate mofetil—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Pentazocine—Vertigo—Lisinopril—systemic scleroderma	0.00271	0.00271	CcSEcCtD
Pentazocine—Diarrhoea—Mometasone—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Pentazocine—Syncope—Lisinopril—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Pentazocine—Shock—Mycophenolic acid—systemic scleroderma	0.00269	0.00269	CcSEcCtD
Pentazocine—Hypotension—Leflunomide—systemic scleroderma	0.00267	0.00267	CcSEcCtD
Pentazocine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Pentazocine—Loss of consciousness—Lisinopril—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Pentazocine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00264	0.00264	CcSEcCtD
Pentazocine—Visual disturbance—Methotrexate—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Pentazocine—Anorexia—Mycophenolic acid—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Pentazocine—Insomnia—Leflunomide—systemic scleroderma	0.00259	0.00259	CcSEcCtD
Pentazocine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Pentazocine—Paraesthesia—Leflunomide—systemic scleroderma	0.00257	0.00257	CcSEcCtD
Pentazocine—Dyspnoea—Leflunomide—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Pentazocine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Pentazocine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Pentazocine—Vomiting—Mometasone—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Pentazocine—Dry mouth—Lisinopril—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Pentazocine—Sweating increased—Prednisone—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Pentazocine—Feeling abnormal—Azathioprine—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Pentazocine—Asthenia—Captopril—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Pentazocine—Dermatitis—Mometasone—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Pentazocine—Decreased appetite—Leflunomide—systemic scleroderma	0.00249	0.00249	CcSEcCtD
Pentazocine—Confusional state—Lisinopril—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Pentazocine—Headache—Mometasone—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Pentazocine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00247	0.00247	CcSEcCtD
Pentazocine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00247	0.00247	CcSEcCtD
Pentazocine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Pentazocine—Pruritus—Captopril—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Pentazocine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Pentazocine—Constipation—Leflunomide—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Pentazocine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Pentazocine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Pentazocine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Pentazocine—Shock—Lisinopril—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Pentazocine—Tachycardia—Lisinopril—systemic scleroderma	0.0024	0.0024	CcSEcCtD
Pentazocine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Pentazocine—Diarrhoea—Captopril—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Pentazocine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Pentazocine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Pentazocine—Irritability—Methotrexate—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Pentazocine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Pentazocine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00236	0.00236	CcSEcCtD
Pentazocine—Nausea—Mometasone—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Pentazocine—Anorexia—Lisinopril—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Pentazocine—Constipation—Mycophenolic acid—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Pentazocine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00232	0.00232	CcSEcCtD
Pentazocine—Hypotension—Lisinopril—systemic scleroderma	0.0023	0.0023	CcSEcCtD
Pentazocine—Dizziness—Captopril—systemic scleroderma	0.0023	0.0023	CcSEcCtD
Pentazocine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00228	0.00228	CcSEcCtD
Pentazocine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00225	0.00225	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Pentazocine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00223	0.00223	CcSEcCtD
Pentazocine—Insomnia—Lisinopril—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Pentazocine—Paraesthesia—Lisinopril—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Pentazocine—Vomiting—Captopril—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Pentazocine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Pentazocine—Dyspnoea—Lisinopril—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Pentazocine—Dermatitis—Captopril—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Pentazocine—Somnolence—Lisinopril—systemic scleroderma	0.00219	0.00219	CcSEcCtD
Pentazocine—Headache—Captopril—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Pentazocine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Pentazocine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Pentazocine—Decreased appetite—Lisinopril—systemic scleroderma	0.00214	0.00214	CcSEcCtD
Pentazocine—Eosinophilia—Methotrexate—systemic scleroderma	0.00212	0.00212	CcSEcCtD
Pentazocine—Shock—Mycophenolate mofetil—systemic scleroderma	0.00212	0.00212	CcSEcCtD
Pentazocine—Hypersensitivity—Leflunomide—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Pentazocine—Constipation—Lisinopril—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Pentazocine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Pentazocine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Pentazocine—Diarrhoea—Azathioprine—systemic scleroderma	0.00207	0.00207	CcSEcCtD
Pentazocine—Nausea—Captopril—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Pentazocine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Pentazocine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Pentazocine—Asthenia—Leflunomide—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Pentazocine—Hallucination—Prednisone—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Pentazocine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Pentazocine—Pruritus—Leflunomide—systemic scleroderma	0.00202	0.00202	CcSEcCtD
Pentazocine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Pentazocine—Dizziness—Azathioprine—systemic scleroderma	0.002	0.002	CcSEcCtD
Pentazocine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Pentazocine—Diarrhoea—Leflunomide—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Pentazocine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Pentazocine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Pentazocine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Pentazocine—Vomiting—Azathioprine—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Pentazocine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Pentazocine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Pentazocine—Dermatitis—Azathioprine—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Pentazocine—Flushing—Prednisone—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Pentazocine—Headache—Azathioprine—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Pentazocine—Dizziness—Leflunomide—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Pentazocine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Pentazocine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Pentazocine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Pentazocine—Sweating—Methotrexate—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Pentazocine—Vomiting—Leflunomide—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Pentazocine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00181	0.00181	CcSEcCtD
Pentazocine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00181	0.00181	CcSEcCtD
Pentazocine—Dermatitis—Leflunomide—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Pentazocine—Nausea—Azathioprine—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Pentazocine—Headache—Leflunomide—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Pentazocine—Agranulocytosis—Methotrexate—systemic scleroderma	0.00179	0.00179	CcSEcCtD
Pentazocine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Pentazocine—Asthenia—Lisinopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Pentazocine—Pruritus—Lisinopril—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Pentazocine—Vomiting—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Pentazocine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Pentazocine—Headache—Mycophenolic acid—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Pentazocine—Nausea—Leflunomide—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Pentazocine—Vision blurred—Prednisone—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Pentazocine—Diarrhoea—Lisinopril—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Pentazocine—Visual impairment—Methotrexate—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Pentazocine—Agitation—Prednisone—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Pentazocine—Dizziness—Lisinopril—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Pentazocine—Erythema multiforme—Methotrexate—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Pentazocine—Nausea—Mycophenolic acid—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Pentazocine—Vertigo—Prednisone—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Pentazocine—Syncope—Prednisone—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Pentazocine—Tinnitus—Methotrexate—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Pentazocine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Pentazocine—Loss of consciousness—Prednisone—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Pentazocine—Vomiting—Lisinopril—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Pentazocine—Dermatitis—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Pentazocine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Pentazocine—Hypertension—Prednisone—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Pentazocine—Chills—Methotrexate—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Pentazocine—Headache—Lisinopril—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Pentazocine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Pentazocine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Pentazocine—Dysgeusia—Methotrexate—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Pentazocine—Nausea—Lisinopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Pentazocine—Anaphylactic shock—Prednisone—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Pentazocine—Shock—Prednisone—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Pentazocine—Tachycardia—Prednisone—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Pentazocine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Pentazocine—Hyperhidrosis—Prednisone—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Pentazocine—Vision blurred—Methotrexate—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Pentazocine—Anorexia—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Pentazocine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Pentazocine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Pentazocine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Pentazocine—Vertigo—Methotrexate—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Pentazocine—Insomnia—Prednisone—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Pentazocine—Paraesthesia—Prednisone—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Pentazocine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Pentazocine—Decreased appetite—Prednisone—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Pentazocine—Constipation—Prednisone—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Pentazocine—Confusional state—Methotrexate—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Pentazocine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Pentazocine—Feeling abnormal—Prednisone—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Pentazocine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Pentazocine—Anorexia—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Pentazocine—Hypotension—Methotrexate—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Pentazocine—Insomnia—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Pentazocine—Paraesthesia—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Pentazocine—Dyspnoea—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Pentazocine—Somnolence—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Pentazocine—Hypersensitivity—Prednisone—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Pentazocine—Decreased appetite—Methotrexate—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Pentazocine—Asthenia—Prednisone—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Pentazocine—Pruritus—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Pentazocine—Feeling abnormal—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Pentazocine—Diarrhoea—Prednisone—systemic scleroderma	0.000999	0.000999	CcSEcCtD
Pentazocine—Dizziness—Prednisone—systemic scleroderma	0.000966	0.000966	CcSEcCtD
Pentazocine—Vomiting—Prednisone—systemic scleroderma	0.000928	0.000928	CcSEcCtD
Pentazocine—Dermatitis—Prednisone—systemic scleroderma	0.00092	0.00092	CcSEcCtD
Pentazocine—Headache—Prednisone—systemic scleroderma	0.000915	0.000915	CcSEcCtD
Pentazocine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000899	0.000899	CcSEcCtD
Pentazocine—Asthenia—Methotrexate—systemic scleroderma	0.000876	0.000876	CcSEcCtD
Pentazocine—Nausea—Prednisone—systemic scleroderma	0.000867	0.000867	CcSEcCtD
Pentazocine—Pruritus—Methotrexate—systemic scleroderma	0.000863	0.000863	CcSEcCtD
Pentazocine—Diarrhoea—Methotrexate—systemic scleroderma	0.000835	0.000835	CcSEcCtD
Pentazocine—Dizziness—Methotrexate—systemic scleroderma	0.000807	0.000807	CcSEcCtD
Pentazocine—Vomiting—Methotrexate—systemic scleroderma	0.000776	0.000776	CcSEcCtD
Pentazocine—Dermatitis—Methotrexate—systemic scleroderma	0.000769	0.000769	CcSEcCtD
Pentazocine—Headache—Methotrexate—systemic scleroderma	0.000765	0.000765	CcSEcCtD
Pentazocine—Nausea—Methotrexate—systemic scleroderma	0.000725	0.000725	CcSEcCtD
